Tasigna bests Gleevec in pivotal first-line chronic myeloid leukaemia trial
This article was originally published in Scrip
Executive Summary
Novartis's Tasigna (nilotinib), its follow-on to its drug Gleevec/Glivec (imatinib), has met its primary endpoint of major molecular response (MMR) in its first Phase III first-line trial designed to show its superiority over the older drug, which has revolutionised the treatment of chronic myeloid leukaemia (CML).